This finding is particularly relevant as the interplay between the PI3K/Akt/mTOR and p53 pathways is a critical determinant of cell fate, and their co-dysregulation is a common feature of glioma progression and therapy resistance (Barzegar Behrooz et al., 2022; Kuduvalli et al., 2023; Mao et al., 2012). The gene discussed is AKT1; the disease is central nervous system cancer.